Cargando…

Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy

Currently, neoadjuvant chemotherapy is a standard therapeutic strategy for breast cancer, as it can provide timely and individualized chemo-sensitivity information and is beneficial for custom-designing subsequent treatment strategies. To accurately select candidates for neoadjuvant chemotherapy, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xinyan, Wang, Mozhi, Wang, Mengshen, Yu, Xueting, Guo, Jingyi, Sun, Tie, Yao, Litong, Zhang, Qiang, Xu, Yingying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933033/ https://www.ncbi.nlm.nih.gov/pubmed/31897326 http://dx.doi.org/10.4048/jbc.2019.22.e49

Ejemplares similares

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?—a meta-analysis of randomized controlled trials
por: Dong, Haoran, et al.
Publicado: (2020)

Nomogram for predicting axillary lymph node status after neoadjuvant chemotherapy in breast cancer
por: Wang, Mengshen, et al.
Publicado: (2020)

The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study
por: Yao, Litong, et al.
Publicado: (2022)

Updated Bayesian Network Meta-Analysis of Adjuvant Targeted Treatment Regimens for Early Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer
por: Li, Xinyan, et al.
Publicado: (2020)

An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector Machine
por: Wang, Mozhi, et al.
Publicado: (2021)

Predicting Pathological Complete Response in Breast Cancer After Two Cycles of Neoadjuvant Chemotherapy by Tumor Reduction Rate: A Retrospective Case-Control Study
por: Yao, Litong, et al.
Publicado: (2023)

Exploring the Metabolic Vulnerabilities of Epithelial–Mesenchymal Transition in Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Role of Proton-Coupled Monocarboxylate Transporters in Cancer: From Metabolic Crosstalk to Therapeutic Potential
por: Sun, Xiangyu, et al.
Publicado: (2020)

HIF-1-induced mitochondrial ribosome protein L52: a mechanism for breast cancer cellular adaptation and metastatic initiation in response to hypoxia
por: Li, Xinyan, et al.
Publicado: (2021)

ARHGAP39 is a prognostic biomarker involved in immune infiltration in breast cancer
por: Yao, Litong, et al.
Publicado: (2023)

Long non‐coding RNA‐CTD‐2108O9.1 represses breast cancer metastasis by influencing leukemia inhibitory factor receptor
por: Wang, Mozhi, et al.
Publicado: (2018)

A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity
por: Wang, Yusong, et al.
Publicado: (2023)

A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer
por: Li, Yijun, et al.
Publicado: (2021)

Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2021)

A generalized non-linear model predicting efficacy of neoadjuvant therapy in HER2+ breast cancer
por: Wang, Yusong, et al.
Publicado: (2023)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
por: KAWAJIRI, HIDEMI, et al.
Publicado: (2014)

Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response
por: Resende, Uanderson, et al.
Publicado: (2019)

Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer
por: Ma, Ge, et al.
Publicado: (2020)

KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer
por: Yao, Litong, et al.
Publicado: (2023)

The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
por: Mark, Kenneth M. K., et al.
Publicado: (2017)

Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy
por: Ai, Xiang, et al.
Publicado: (2020)

Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2020)

Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy
por: Wang, Wenyan, et al.
Publicado: (2022)

Early prediction of pathological outcomes to neoadjuvant chemotherapy in breast cancer patients using automated breast ultrasound
por: Wang, Xinguang, et al.
Publicado: (2016)

Peripheral Blood Cell Ratios as Prognostic Indicators in a Neoadjuvant Chemotherapy-Treated Breast Cancer Cohort
por: Jalali, Amirhossein, et al.
Publicado: (2022)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

Pre‐treatment systemic immune‐inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy
por: Chen, Li, et al.
Publicado: (2020)

Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients
por: Zhang, Jieqiu, et al.
Publicado: (2023)

Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
por: Xu, Yaqian, et al.
Publicado: (2020)

Early changes of platelet‑lymphocyte ratio correlate with neoadjuvant chemotherapy response and predict pathological complete response in breast cancer
por: Dan, Jiaqiang, et al.
Publicado: (2023)

The association between breast density and breast cancer pathological response to neoadjuvant chemotherapy
por: Cullinane, C., et al.
Publicado: (2022)

Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer
por: Kim, Jee Ye, et al.
Publicado: (2015)

A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma
por: Kunnuru, Supreeth Kumar Reddy, et al.
Publicado: (2020)

Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy
por: Tan, Shirong, et al.
Publicado: (2021)

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alba, Emilio, et al.
Publicado: (2016)

Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer
por: Joo, Sunghoon, et al.
Publicado: (2021)

Contrast-enhanced ultrasonography for early prediction of response of neoadjuvant chemotherapy in breast cancer
por: Guo, Jiabao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gk60aah3jjq6vsojpq36bgblqr